Pfizer unveils positive phase 3 trial results for RSV vaccine

Pfizer (PFE) has released the results from its Phase 3 clinical trial for its RSV vaccine. The trial showed positive outcomes for adults aged 18-59, widening the population that can potentially benefit from the vaccine. Previously, Pfizer's RSV vaccine had been approved for use in pregnant women and adults aged 60 and older.

Yahoo Finance's Health Reporter Anjalee Khemlani breaks down the details.

For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime.

Editor's note: This article was written by Angel Smith

Video transcript

JOSH LIPTON: Pfizer's phase III study of its RSV vaccine showing promising results for adults under the age of 60. Here with the details is Yahoo Finance's Anjalee Khemlani.

ANJALEE KHEMLANI: Hey, guys. Yeah, no surprise here with Pfizer getting the positive phase III results for adults ages 18 through 59. That already adds to the body of knowledge that is with its vaccine that is already approved for ages 60 and older, as well as the maternal population. So pregnant mothers who have been taking this vaccine later on in the weeks of pregnancy.

So really good news for Pfizer. It's something that the investors have been waiting for because it really expands who Pfizer can cater to. Right now, they're the only ones on the market with that maternal vaccine. So approved for pregnant women, as well as for 16 and older.

But they do have some competition nipping at their heels. GSK was the first out the door with 60 and older. Meanwhile, Moderna also in some phase, later phase trials for ages 60 and older, as well as a pediatric population.

So Pfizer is quite ahead of the game in that respect. So good for them. And if the FDA does approve this, does mean that Pfizer would have a really strong market share.

JULIE HYMAN: Well, but how big is the market? I mean, my understanding was always that you didn't need to get this thing unless you were over 60 or a child. Is it just other at risk, and how big a market really is that?

ANJALEE KHEMLANI: Yes, it is just those who are immunocompromised, those who are likely to get it. So while it isn't necessarily as large a market, it does give them really good footing when it comes to the broader RSV market. They can have sort of different populations for it.

And they do have a focus on the younger. That pediatric population is really the one that still needs catering to. So it's interesting that no one has been able to really corner that part of the market just yet because that is where we've seen the highest number of illnesses throughout the respiratory virus season.

And that's where the focus is. But meanwhile, they do have basically everything else under the umbrella covered here.

JULIE HYMAN: Interesting. All right. Thanks so much. Appreciate it.